Cardiovascular disease and chronic kidney disease: Insights and an update

被引:56
作者
Best, PJM
Reddan, DN
Berger, PB
Szczech, LA
McCullough, PA
Califf, RM
机构
[1] Mayo Clin & Mayo Fdn, Div Cardiovasc Dis W16, Rochester, MN 55905 USA
[2] Duke Clin Res Inst, Div Nephrol & Cardiovasc Dis, Durham, NC USA
[3] William Beaumont Hosp, Div Cardiovasc Dis, Royal Oak, MI 48072 USA
关键词
D O I
10.1016/j.ahj.2004.04.011
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Despite the high prevalence and significant morbidity and mortality rates of chronic kidney disease (CKD) related to cardiovascular disease, it remains vastly understudied. Most of the current practice recommendations come from small underpowered prospective studies, retrospective reviews, and assuming patients with CKD will similarly benefit from medications and treatments as patients with normal renal function. In addition, because of the previous lack of a consistent definition of, CKD and how to measure renal function, definitions of the degree of renal dysfunction have varied widely and compounded the confusion of these data. Remarkably, despite patients with CKD representing the group at highest risk from cardiovascular complications, even greater than patients with diabetes mellitus, there has been a systematic exclusion of patients with CKD from therapeutic trials. This review outlines our current understanding of CKD as a cardiovascular risk factor, treatment options, and the future directions that are needed to treat cardiovascular disease in patients with CKD.
引用
收藏
页码:230 / 242
页数:13
相关论文
共 152 条
[21]  
BRUNNER FP, 1992, KIDNEY INT, V42, pS4
[22]   DELAYED ELIMINATION OF ENOXAPARINE IN PATIENTS WITH CHRONIC RENAL-INSUFFICIENCY [J].
CADROY, Y ;
POURRAT, J ;
BALADRE, MF ;
SAIVIN, S ;
HOUIN, G ;
MONTASTRUC, JL ;
VERNIER, I ;
BONEU, B .
THROMBOSIS RESEARCH, 1991, 63 (03) :385-390
[23]   Vintage, nutritional status, and survival in hemodialysis patients [J].
Chertow, GM ;
Johansen, KL ;
Lew, N ;
Lazarus, JM ;
Lowrie, EG .
KIDNEY INTERNATIONAL, 2000, 57 (03) :1176-1181
[24]   Sustained-release diltiazem reduces myocardial ischemic episodes in end-stage renal disease:: A double-blind, randomized, crossover, placebo-controlled trial [J].
Cice, G ;
Di Benedetto, A ;
D'Andrea, A ;
D'Isa, S ;
Ferrara, L ;
Russo, PE ;
Iacono, A ;
Calabrò, R .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 (04) :1006-1011
[25]  
Cice G, 1998, Cardiologia, V43, P597
[26]   Homocysteine and risk of ischemic heart disease and stroke -: A meta-analysis [J].
Clarke, R ;
Collins, R ;
Lewington, S ;
Donald, A ;
Alfthan, G ;
Tuomilehto, J ;
Arnesen, E ;
Bonaa, K ;
Blacher, J ;
Boers, GHJ ;
Bostom, A ;
Bots, ML ;
Grobee, DE ;
Brattström, L ;
Breteler, MMB ;
Hofman, A ;
Chambers, JC ;
Kooner, JS ;
Coull, BM ;
Evans, RW ;
Kuller, LH ;
Evers, S ;
Folsom, AR ;
Freyburger, G ;
Parrot, F ;
Genst, J ;
Dalery, K ;
Graham, IM ;
Daly, L ;
Hoogeveen, EK ;
Kostense, PJ ;
Stehouwer, CDA ;
Hopknis, PN ;
Jacques, P ;
Selhub, J ;
Luft, FC ;
Jungers, P ;
Lindgren, A ;
Lolin, YI ;
Loehrer, F ;
Fowler, B ;
Mansoor, MA ;
Malinow, MR ;
Ducimetiere, P ;
Nygard, O ;
Refsum, H ;
Vollset, SE ;
Ueland, PM ;
Omenn, GS ;
Beresford, SAA .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2002, 288 (16) :2015-2022
[27]   PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE [J].
COCKCROFT, DW ;
GAULT, MH .
NEPHRON, 1976, 16 (01) :31-41
[28]   Susceptibility of plasma low- and high-density lipoproteins to oxidation in patients with severe hyperhomocysteinemia [J].
CordobaPorras, A ;
SanchezQuesada, JL ;
GonzalezSastre, F ;
OrdonezLlanos, J ;
BlancoVaca, F .
JOURNAL OF MOLECULAR MEDICINE-JMM, 1996, 74 (12) :771-776
[29]  
Cornelli U, 1999, SEMIN THROMB HEMOST, V25, P57
[30]   Prevalence and correlates of elevated serum creatinine levels - The Framingham heart study [J].
Culleton, BF ;
Larson, MG ;
Evans, JC ;
Wilson, PWF ;
Barrett, BJ ;
Parfrey, PS ;
Levy, D .
ARCHIVES OF INTERNAL MEDICINE, 1999, 159 (15) :1785-1790